European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968, September 2005

Curcumin: The story so far

  • R.A. Sharma

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton SM2 5PT, UK. Tel.: +44 208 642 6011; fax: +44 208 661 3127.
  • ,
  • A.J. Gescher
  • ,
  • W.P. Steward

Received 15 March 2005; accepted 13 May 2005.

Abstract 

Curcumin is a polyphenol derived from the herbal remedy and dietary spice turmeric. It possesses diverse anti-inflammatory and anti-cancer properties following oral or topical administration. Apart from curcumin’s potent antioxidant capacity at neutral and acidic pH, its mechanisms of action include inhibition of several cell signalling pathways at multiple levels, effects on cellular enzymes such as cyclooxygenase and glutathione S-transferases, immuno-modulation and effects on angiogenesis and cell–cell adhesion. Curcumin’s ability to affect gene transcription and to induce apoptosis in preclinical models is likely to be of particular relevance to cancer chemoprevention and chemotherapy in patients. Although curcumin’s low systemic bioavailability following oral dosing may limit access of sufficient concentrations for pharmacological effect in certain tissues, the attainment of biologically active levels in the gastrointestinal tract has been demonstrated in animals and humans. Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.

Keywords: Carcinogenesis, Colorectal cancer, Chemoprevention

 

PII: S0959-8049(05)00477-6

doi:10.1016/j.ejca.2005.05.009

European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968, September 2005